Stay updated with breaking news from Breyanzi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted priority review to the supplemental biologics license application seeking approval to expand the indication of lisocabtagene maraleucel to include patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a BTK inhibitor and a BCL-2 inhibitor. ....
Loretta J. Nastoupil, MD, discusses the rationale for investigating the use of lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma. ....
Pivotal trials TRANSCEND FL and TRANSCEND NHL 001 continue to underscore the transformative potential of Breyanzi and its clinically meaningful benefit across the broadest array of B-cell. | May 30, 2023 ....
The European Commission has approved lisocabtagene maraleucel for the treatment of adult patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. ....